Tanvex BioPharma (TPE:6541) ROCE % : -73.34% (As of Mar. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Tanvex BioPharma ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Tanvex BioPharma's annualized ROCE % for the quarter that ended in Mar. 2024 was -73.34%.

Tanvex BioPharma ROCE % Historical Data

The historical data trend for Tanvex BioPharma's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tanvex BioPharma ROCE % Chart

Tanvex BioPharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-59.66

-56.97

-35.29

-41.85

-75.39

Tanvex BioPharma Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															-82.43	-64.32	-60.28	-73.40	-73.34

Tanvex BioPharma ROCE % Calculation

Tanvex BioPharma's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-2079.289	/	( ( (3419.816 - 303.285)	+	(2763.403 - 363.73) )	/ 2 )
	=	-2079.289	/	( (3116.531	+	2399.673)	/ 2 )
	=	-2079.289	/	2758.102
	=	-75.39 %

Tanvex BioPharma's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	-1615.06	/	( ( (2763.403 - 363.73)	+	(2765.273 - 760.392) )	/ 2 )
	=	-1615.06	/	( ( 2399.673	+	2004.881 )	/ 2 )
	=	-1615.06	/	2202.277
	=	-73.34 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Tanvex BioPharma (TPE:6541) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Tanvex BioPharma ROCE % Related Terms

Thank you for viewing the detailed overview of Tanvex BioPharma's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Tanvex BioPharma (TPE:6541) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tanvex BioPharma Inc (TPE:6541) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 376, Ren'ai Road, Section 4, 13th Floor-1, Da'an District, Taipei, TWN, 106

Website

https://www.tanvex.com

Tanvex BioPharma Inc is a biopharmaceutical company. It is engaged in the research, development, manufacture, and sale of biosimilar products. The company's products are used to cure diseases such as Neutropenia, Breast Cancer, Metastatic Colorectal Cancer, and others.

Tanvex BioPharma (TPE:6541) Headlines

No Headlines